SpO2 Validation Study-Philips Optimus
Terminated · NCT07215429
Conditions: Pulse Oximetry, Oxygen Measurements, SpO2
At a glance
- Research payments reported, 2025
- $103,277
- U.S. investigators named
- 2
- Sites paid
- 2
- Planned or actual enrollment
- 24
About the trial
- Sponsor
- Philips Clinical & Medical Affairs Global
- Tested
- No intervention (device)
- Dates
- Started 2025-09-09; completion 2025-09-19
- Results posted
- Not yet
Validation study to validate the SpO2 accuracy performance of the Sponsor's SpO2 sensors over the range of 70-100% SaO2 during non-motion conditions assessed by CO-Oximetry
From ClinicalTrials.gov, last updated 2026-04-13. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Philips North America LLC reported $103,277 in research payments for this study in 2025 (3 payments).
Products named: Optimus Rad and Rf
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Philip E. Bickler, MD Anesthesiology · San Francisco, CA
- Monica M. Rabanal, NP Nurse Practitioners · Evergreen, CO
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- UCSF Langley Porter Psychiatric Hospital and Clinics, CA $96,297
- Element Materials Technology $6,980
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.